Tipifarnib
- Generic Name
- Tipifarnib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4O
- CAS Number
- 192185-72-1
- Unique Ingredient Identifier
- MAT637500A
- Background
Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
- Indication
Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Pure Erythroid LeukemiaRecurrent Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Myelomonocytic LeukemiaRecurrent DiseaseAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal Differentiation
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00383474
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00360776
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT00335764
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 109
- Registration Number
- NCT00281957
- Locations
- 🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States
🇺🇸El Camino Hospital, Mountain View, California, United States
🇺🇸Great Falls Clinic, Great Falls, Montana, United States
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00244972
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00243035
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-11-14
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 40
- Registration Number
- NCT00210028
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Institut Val d'Aurelle_ Paul Lamarque, Montpellier, France
🇫🇷Institut Claudius Regaud, Toulouse, France
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 27
- Registration Number
- NCT00209989
- Locations
- 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷Centre Jean Perrin, Clermont Ferrand, France
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2013-05-03
- Target Recruit Count
- 30
- Registration Number
- NCT00124644
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00112853
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.